Significant targetable genomic alterations (GAs) discovered by NGS assessment of 29 cases of adrenocortical carcinoma (ACC)
| Gene (frequency in ACC) | GAs | Total cases with targetable GAs | Potential targeted therapeutic | |||
|---|---|---|---|---|---|---|
| Loss (homozygous deletion) | Base substitution | Truncation | Amplification | |||
| NF1 (17%) | 5 | 4 (1 case with 2 NF1 GAs) | Everolimus Temsirolimus | |||
| CDKN2A/B (14%) | 3 | 1 | 4 | CDK 4/6 inhibitors | ||
| ATM (10%) | 3 | 3 | Everolimus Temsirolimus | |||
| CDK4 (7%) | 2 | 2 | CDK 4/6 inhibitors | |||
| EGFR (3%) | 1 | 1 | Erlotinib Gefitinib | |||
| PDGFRB (3%) | 1 | 1 | Dasatinib Imatinib Sorafenib Sunitinib | |||
| PTCH1 (3%) | 1 | 1 | Vismodegib | |||
| PIK3CA (3%) | 1 | 1 | Everolimus Temsirolimus | |||
NGS, next-generation sequencing.